Please try another search
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Alan K. Yamashita | 70 | 2019 | Non-Executive Director |
Pam McCombe | - | - | Scientific Advisor |
Peter Brooks | - | - | Scientific Advisor |
Eicke Latz | - | - | Scientific Advisor |
Andreas Suhrbier | - | - | Scientific Advisor |
Thian Chew | - | 2017 | Executive Chairman & CEO |
Alistair W. Bennallack | - | 2020 | Non-Executive Director |
Nathan Lawrentschuk | - | 2019 | Member of Scientific Advisory Board |
Louis Irving | - | 2019 | Member of Scientific Advisory Board |
Lynda Spelman | - | 2019 | Member of Scientific Advisory Board |
Robert Merriel | - | 2020 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review